Zivo Bioscience, Inc (ZIVO) insider trading
Every open-market stock purchase and sale by Zivo Bioscience, Inc executives, directors, large shareholders and members of Congress, from SEC Form 4 filings. Sector: Other.
Insider activity at a glance
- Insiders bought $1.2M over the last 12 months (12 buys).
- Last insider buy: Mark E Strome (10% owner), $200K, 6 months ago.
Last 12 months: insiders bought $1.2M (12 buys) and sold $0 (0 sales). Last close $3.05 on Jun 4, 2026.
Recent ZIVO insider trades
| Date | Insider | Trade | Value |
|---|---|---|---|
| Apr 17, 2026 | Mark E Strome (10% owner) | Bought | $200K |
| Feb 27, 2026 | Laith L Yaldoo (Insider) | Bought | $15K |
| Feb 12, 2026 | Mark E Strome (10% owner) | Bought | $195K |
| Feb 12, 2026 | Mark E Strome (10% owner) | Bought | — |
| Feb 10, 2026 | Laith L Yaldoo (Insider) | Bought | $25K |
| Jan 26, 2026 | John Bernard Payne (CEO) | Bought | $100K |
| Jan 26, 2026 | Alison A Cornell (Insider) | Bought | $100K |
| Jan 14, 2026 | Laith L Yaldoo (Insider) | Bought | $15K |
| Jan 14, 2026 | Christopher D. Maggiore (Insider) | Bought | $15K |
| Nov 28, 2025 | Laith L Yaldoo (10% owner) | Bought | $25K |
| Oct 13, 2025 | Mark E Strome (10% owner) | Bought | $250K |
| Oct 13, 2025 | Mark E Strome (10% owner) | Bought | — |
| Oct 10, 2025 | Laith L Yaldoo (Insider) | Bought | $20K |
| Oct 8, 2025 | Christopher D. Maggiore (Insider) | Bought | $284K |
| Oct 2, 2025 | Alison A Cornell (Insider) | Bought (not open market) | $12.5K |
| Oct 2, 2025 | Christopher D. Maggiore (Insider) | Bought (not open market) | $11K |
| Oct 2, 2025 | Laith L Yaldoo (Insider) | Bought (not open market) | $9.4K |
Who's trading ZIVO
- Mark E Strome, 10% owner: bought $645K (5 buys), last Apr 17, 2026
- Laith L Yaldoo, Insider: bought $100K (5 buys), last Feb 27, 2026
- Alison A Cornell, Insider: bought $100K (1 buy), last Jan 26, 2026
- John Bernard Payne, CEO: bought $100K (1 buy), last Jan 26, 2026
- Christopher D. Maggiore, Insider: bought $299K (2 buys), last Jan 14, 2026
Get free alerts when an insider at Zivo Bioscience, Inc files a new trade →